Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status By Ogkologos - December 17, 2024 450 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT Detects More Lower-Stage CRCs than Usual Care MOST POPULAR EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... January 30, 2020 Why is Colorectal Cancer Rising Rapidly among Young Adults? November 5, 2020 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 Load more HOT NEWS Coronavirus reports – Part 6 “The kids being home all the... 4-Year-Old Boy Calls Police To Tell Them About His Toys, Cop... Holiday Travel: 11 Things To Know Before Hitting The Road With... FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer
